Cited by 1,460Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Open access

Johannessen, Cory M., Boehm, Jesse S., Kim, So Young, Thomas, Sapana R., Wardwell, Leslie, Johnson, Laura A., Emery, Caroline M., Stransky, Nicolas, Cogdill, Alexandria P., Barretina, Jordi, Caponigro, Giordano, Hieronymus, Haley, Murray, Ryan R., Salehi-Ashtiani, Kourosh, Hill, David E., Vidal, Marc, Zhao, Jean J., Yang, Xiaoping, Alkan, Ozan, Kim, Sungjoon, Harris, Jennifer L., Wilson, Christopher J., Myer, Vic E., Finan, Peter M., Root, David E., Roberts, Thomas M., Golub, Todd, Flaherty, Keith T., Dummer, Reinhard, Weber, Barbara L., Sellers, William R., Schlegel, Robert, Wargo, Jennifer A., Hahn, William C., Garraway, Levi A.·2010·Nature

DOI 10.1038/nature09627PMC PMC3058384

Open this paper in CoChat — free account

Abstract

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09627

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citation
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497

Show all 30 references

Sorted by citations

Items 301–400 of 1,002

MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0022 · Cited by 102
Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
BRAF V600E mutation in hairy cell leukemia: from bench to bedside
Falini, B., Martelli, M. P., & Tiacci, E. (2016) · Blood · doi:10.1182/blood-2016-07-418434 · Cited by 102
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 101
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Huelse, J. M., Fridlyand, D. M., Earp, S. H., DeRyckere, D., & Graham, D. K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107577 · Cited by 101
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., Cassinelli, G., Lanzi, C., Testi, M., Rivoltini, L., et al. (2011) · Neoplasia · doi:10.1593/neo.111102 · Cited by 99
P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
Sun, H., Li, Y., Tian, S., Wang, J., & Hou, T. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003729 · Cited by 100
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.418 · Cited by 103
A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Waizenegger, I. C., Baum, A., Steurer, S., Stadtmüller, H., Bader, G., Schaaf, O., Garin‐Chesa, P., Schlattl, A., Schweifer, N., Haslinger, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0617 · Cited by 101
Resistance to Molecularly Targeted Therapies in Melanoma
Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021) · Cancers · doi:10.3390/cancers13051115 · Cited by 104
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 106
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
Faião‐Flores, F., Alves-Fernandes, D. K., Pennacchi, P. C., Sandri, S., Vicente, A. L. S. A., Scapulatempo‐Neto, C., Vazquez, V. D. L., Reis, R. M., Chauhan, J. S., Goding, C. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.348 · Cited by 101
Hexokinase activity is required for recruitment of parkin to depolarized mitochondria
McCoy, M. K., Kaganovich, A., Rudenko, I. N., Ding, J., & Cookson, M. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt407 · Cited by 97
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Weide, B., Eigentler, T., Pflugfelder, A., Zelba, H., Martens, A., Pawelec, G., Giovannoni, L., Ruffini, P. A., Elia, G., Neri, D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0206 · Cited by 99
JUMP Cell Painting chemical dataset: Morphological map of 115,796 compounds in human cellsPreprint
Chandrasekaran, S. N., Ackerman, J., Alix, E., Akella, L. B., Arévalo, J., Alix, E., Ando, D. M., Arévalo, J., Boyd, J. D., Brino, L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.23.534023 · Cited by 112
Self-citation
Targeting MAPK pathway in melanoma therapy
Cheng, Y., Zhang, G., & Li, G. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9433-9 · Cited by 99
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 97
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J. C., Kamarashev, J. A., Frederick, D. T., Cooper, Z. A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160855 · Cited by 95
Self-citation
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Light Activation of Protein Splicing with a Photocaged Fast Intein
Ren, W., Ji, A., & Ai, H. (2015) · Journal of the American Chemical Society · doi:10.1021/ja508597d · Cited by 94
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 94
Self-citation
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 94
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 94
Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling
Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 101
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells
Xie, C., Liu, X., Sham, K. W. Y., Lai, J. M. Y., & Cheng, C. H. K. (2014) · Autophagy · doi:10.4161/auto.29164 · Cited by 94
The Akt signaling pathway
Madhunapantula, S. V., Mosca, P. J., & Robertson, G. P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18442 · Cited by 96
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Niehr, F., von Euw, E., Attar, N., Guo, D., Matsunaga, D. R., Sazegar, H., Ng, C., Glaspy, J. A., Recio, J. A., Lo, R. S., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-76 · Cited by 98
Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
Jang, S., & Atkins, M. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.197 · Cited by 98
TPL2 kinase regulates the inflammatory milieu of the myeloma niche
Hope, C. L., Ollar, S. J., Héninger, E., Hebron, E., Jensen, J. L., Kim, J., Maroulakou, I. G., Miyamoto, S., Leith, C. P., Yang, D. T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554071 · Cited by 95
MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.012 · Cited by 95
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Datta, J., Damodaran, S., Parks, H., Ocrainiciuc, C., Miya, J., Yu, L., Gardner, E. P., Samorodnitsky, E., Wing, M. R., Bhatt, D., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1010 · Cited by 93
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 94
Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Pritchard, A. L., & Hayward, N. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0383 · Cited by 97
Targeted Therapy for Melanoma
Wong, D. J. L., & Ribas, A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_10 · Cited by 96
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0348 · Cited by 92
Self-citation
Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas
Newman, S., Fan, L., Pribnow, A. K., Silkov, A., Rice, S. V., Lee, S., Shao, Y., Shaner, B., Mulder, H. L., Nakitandwe, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0373-y · Cited by 93
A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways
Huang, T., Alvarez, A. A., Pangeni, R. P., Horbinski, C., Lu, S., Kim, S.-H., James, C. D., Raizer, J. J., Kessler, J. A., Brenann, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms12885 · Cited by 96
Self-citation
Intratumoral Heterogeneity as a Therapy Resistance Mechanism
Somasundaram, R., Villanueva, J., & Herlyn, M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00011-7 · Cited by 91
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Iniguez, A. B., Alexe, G., Wang, E. J., Roti, G., Patel, S., Chen, L., Kitara, S., Conway, A. S., Robichaud, A. L., Stolte, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.005 · Cited by 92
Self-citation
TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination
Zhu, G., Herlyn, M., & Yang, X. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00732-8 · Cited by 93
Self-citation
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
Self-citation
Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
Gowrishankar, K., Snoyman, S., Pupo, G. M., Becker, T. M., Kefford, R. F., & Rizos, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.63 · Cited by 92
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Smyth, T., Paraiso, K. H. T., Hearn, K., Rodríguez-López, A. M., Munck, J. M., Haarberg, H. E., Sondak, V. K., Thompson, N. T., Azab, M., Lyons, J. F., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0452 · Cited by 89
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
Mandal, R., Becker, S., & Strebhardt, K. (2015) · Oncogene · doi:10.1038/onc.2015.329 · Cited by 93
Cezanne/OTUD7B is a cell cycle‐regulated deubiquitinase that antagonizes the degradation of APC/C substrates
Bonacci, T., Suzuki, A., Grant, G. D., Stanley, N., Cook, J. G., Brown, N. G., & Emanuele, M. J. (2018) · The EMBO Journal · doi:10.15252/embj.201798701 · Cited by 91
The dynamic nature of the kinome
Graves, L. M., Duncan, J. S., Whittle, M. C., & Johnson, G. L. (2013) · Biochemical Journal · doi:10.1042/bj20121456 · Cited by 93
Mechanisms of Resistance to RAF Inhibitors in Melanoma
Aplin, A. E., Kaplan, F. M., & Shao, Y. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.147 · Cited by 94
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 91
Towards systematic functional characterization of cancer genomes
Boehm, J. S., & Hahn, W. C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3013 · Cited by 84
Self-citation
WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop
Agajanian, M. J., Walker, M. P., Axtman, A. D., Ruela-de-Sousa, R. R., Serafín, D., Rabinowitz, A. D., Graham, D. M., Ryan, M. B., Tamir, T. Y., Nakamichi, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.023 · Cited by 88
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
Song, K., Minami, J. K., Huang, A. J. Y., Dehkordi, S. R., Lomeli, S. H., Luebeck, J., Goodman, M. H., Moriceau, G., Krijgsman, O., Dharanipragada, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0936 · Cited by 85
Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
Ravnan, M. C., & Matalka, M. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.009 · Cited by 90
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Tworkoski, K., Singhal, G., Szpakowski, S., Zito, C. I., Bacchiocchi, A., Muthusamy, V., Bosenberg, M., Krauthammer, M. O., Halaban, R., & Stern, D. F. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0512 · Cited by 89
BRAF in Melanoma: Current Strategies and Future Directions
Salama, A. K. S., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0779 · Cited by 86
Self-citation
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 91
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Narayan, R. S., Molenaar, P., Teng, J., Cornelissen, F. M. G., Roelofs, I., de Menezes, R. X., Dik, R., Lagerweij, T., Broersma, Y., Petersen, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16735-2 · Cited by 89
Tpl2 kinase signal transduction in inflammation and cancer
Vougioukalaki, M., Kanellis, D. C., Gkouskou, K. K., & Eliopoulos, A. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.004 · Cited by 92
BRAF in malignant melanoma progression and metastasis: potentials and challenges.
Alqathama, A. A. (2020) · PubMed Central · Cited by 86
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 92
MITF Modulates Therapeutic Resistance through EGFR Signaling
Ji, Z., Chen, Y. E., Kumar, R., Taylor, M., Njauw, C.-N. J., Miao, B., Frederick, D. T., Wargo, J. A., Flaherty, K. T., Jonsson, G. G., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.105 · Cited by 87
Self-citation
P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma
Ong, C. C., Jubb, A. M., Jakubiak, D., Zhou, W., Rudolph, J., Haverty, P. M., Kowanetz, M., Yan, Y., Tremayne, J. R., Lisle, R., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt054 · Cited by 87
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
Metastatic melanoma treatment: Combining old and new therapies
Davey, R. J., van der Westhuizen, A., & Bowden, N. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.011 · Cited by 90
Targeting the RAS pathway in melanoma
Ji, Z., Flaherty, K. T., & Tsao, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.001 · Cited by 82
Self-citation
Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
Carlino, M. S., Gowrishankar, K., Saunders, C. A. B., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R. P. M., Becker, T. M., Kefford, R. F., Long, G. V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0011 · Cited by 82
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 84
MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 86
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Marusiak, A. A., Edwards, Z. C., Hugo, W., Trotter, E. W., Girotti, M. R., Stephenson, N. L., Kong, X., Gartside, M. G., Fawdar, S., Hudson, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4901 · Cited by 86
New Challenges in Endpoints for Drug Development in Advanced Melanoma
Ribas, A., Hersey, P., Middleton, M. R., Gogas, H. J., Flaherty, K. T., Sondak, V. K., & Kirkwood, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2323 · Cited by 81
Self-citation
Targeting Mutant BRAF in Melanoma
Kudchadkar, R. R., Paraiso, K. H. T., & Smalley, K. S. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b436e · Cited by 80
Epigenetic memory of the first cell fate decision prevents complete ES cell reprogramming into trophoblast
Cambuli, F., Murray, A., Dean, W., Dudzińska, D., Krueger, F., Andrews, S., Senner, C. E., Cook, S. J., & Hemberger, M. (2014) · Nature Communications · doi:10.1038/ncomms6538 · Cited by 80
Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
Hollebecque, A., Malka, D., Ferté, C., Ducreux, M. P., & Boige, V. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.005 · Cited by 79
Targeting NRAS in Melanoma
Kelleher, F. C., & McArthur, G. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824ba4df · Cited by 82
Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment
Wilmott, J. S., Haydu, L. E., Menzies, A. M., Lum, T., Hyman, J., Thompson, J. F., Hersey, P., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302616 · Cited by 78
Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2556 · Cited by 80
Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma
Wang, J. X., Fukunaga‐Kalabis, M., & Herlyn, M. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0349-3 · Cited by 85
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway
Zhou, C., Chen, X., Zeng, W., Peng, C., Huang, G., Li, X., Ouyang, Z., Luo, Y., Xu, X., Xu, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11599 · Cited by 80
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy
Segura, M. F., Greenwald, H. S., Hanniford, D., Osman, I., & Hernando, E. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs205 · Cited by 78
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Lassen, A., Atefi, M. S., Robert, L., Wong, D. J. L., Cerniglia, M., Comin-Anduix, B., & Ribas, A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-83 · Cited by 81
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 79
Physical and functional interactome atlas of human receptor tyrosine kinases
Salokas, K., Öhman, T., Liu, X., Chowdhury, I. M., Gawriyski, L. M., Keskitalo, S., & Varjosalo, M. T. (2022) · EMBO Reports · doi:10.15252/embr.202154041 · Cited by 70
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Sanlorenzo, M., Choudhry, A., Vujic, I., Posch, C., Kim, C. A., Johnston, K., Meier, M. M., Osella‐Abate, S., Quaglino, P., DAUD, A. I., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.002 · Cited by 78
Critical parameters in targeted drug development: the pharmacological audit trail
Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 78
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells
Wu, C., Sim, H., Huang, Y.-H., Liu, Y., Hsiao, S.-H., Cheng, H.-W., Li, Y., Ambudkar, S. V., & Hsu, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.003 · Cited by 77
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
Knauf, J. A., Luckett, K. A., Chen, K.-Y., Voza, F. A., Socci, N. D., Ghossein, R. A., & Fagin, J. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120966 · Cited by 77
Proteome‐wide analysis of phospho‐regulated PDZ domain interactions
Sundell, G. N., Arnold, R. R., Ali, M., Naksukpaiboon, P., Orts, J., Güntert, P., Celestine, N., & Ivarsson, Y. (2018) · Molecular Systems Biology · doi:10.15252/msb.20178129 · Cited by 74
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
Broman, K. K., Dossett, L. A., Sun, J. X., Eroglu, Z., & Zager, J. S. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1607289 · Cited by 76
The multifaceted anti-cancer effects of BRAF-inhibitors
Croce, L., Coperchini, F., Magri, F., Chiovato, L., & Rotondi, M. (2019) · Oncotarget · doi:10.18632/oncotarget.27304 · Cited by 75
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Whittaker, S. R., Cowley, G. S., Wagner, S., Luo, F., Root, D. E., & Garraway, L. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0136-t · Cited by 75
Self-citation
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma
Vieira, G. C., Chockalingam, S., Melegh, Z., Greenhough, A., Malik, S., Szemes, M., Park, J. H., Kaidi, A., Zhou, L., Catchpoole, D. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5548 · Cited by 75
Emerging insights into resistance to BRAF inhibitors in melanoma
Bucheit, A. D., & Davies, M. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.013 · Cited by 77
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 77
Self-citation
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Kim, T. S., Amaria, R. N., Spencer, C. N., Reuben, A., Cooper, Z. A., & Wargo, J. A. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.04.002 · Cited by 76
Self-citation
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863043 · Cited by 80
Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
Vultur, A., Villanueva, J., & Herlyn, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0174 · Cited by 76
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert, J. M., & Kluger, H. M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0249-5 · Cited by 80

Authors: Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
Affiliations: Broad Institute (US)
Harvard University (US)
Massachusetts General Hospital (US)
Genomics Institute of the Novartis Research Foundation (US)
Dana-Farber Cancer Institute (US)
University of Zurich (CH)
Corresponding author: Garraway, Levi A.
ORCID: Johannessen, Cory M.
Boehm, Jesse S.
Kim, So Young
Stransky, Nicolas
Cogdill, Alexandria P.
Barretina, Jordi
Hill, David E.
Vidal, Marc
Zhao, Jean J.
Yang, Xiaoping
Alkan, Ozan
Wilson, Christopher J.
Myer, Vic E.
Root, David E.
Roberts, Thomas M.
Golub, Todd
Flaherty, Keith T.
Dummer, Reinhard
Weber, Barbara L.
Sellers, William R.
Wargo, Jennifer A.
Hahn, William C.
Garraway, Levi A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-11-24
Volume: 468
Issue: 7326
Pages: 968-972
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09627
PMC: PMC3058384
OpenAlex: W2141674733
Cited by: 1,460
References: 30
Citations by year: 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
FWCI: 65.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders: National Institutes of Health (DP2OD002750)
National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
MeSH terms: Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks